Annual Report 2023
2023-08-31
Financial Reports
Annual Reports
Half Year Reports
2024
2024-02-27 ImpediMed Financial Statements – FY2024 Half Year
2023
2022-12-31 ImpediMed Financial Statements – FY2023 Half Year
2023-02-23 Appendix 4D and Interim Financial Report
2023-08-31 Appendix 4E – Financial year ended 30 June 2023
2022
2021-12-31 ImpediMed Financial Statements – FY2022 Half Year
2021
2020-12-31 ImpediMed Financial Statements – FY2021 Half Year
2020
2019-12-31 ImpediMed Financial Statements – FY2020 Half Year
2019
2018-12-31 ImpediMed Financial Statements – FY2019 Half Year
2018
2017-12-31 ImpediMed Financial Statements – FY2018 Half Year
Quarterly Reports
2024
Appendix 4C – Quarter Ended 30 September 2023
31 October 2023
View the PDF
Quarterly Activity Statement and Cash Flow Report
31 January 2024
View the PDF
Quarterly Activity Statement and Cash Flow Report
30 April 2024
View the PDF
2023
Appendix 4C – Quarter Ended 30 September 2023
31 October 2023
View the PDF
Appendix 4C – Quarter Ended 30 June 2023
24 July 2023
View the PDF
Appendix 4C – Quarter Ended 31 March 2023
April 17, 2023
View the PDF
Appendix 4C – Quarter Ended 31 December 2022
30 January 2023
View the PDF
2022
Appendix 4C – Quarter Ended 31 December 2022
January 30, 2023
View the PDF
Appendix 4C – Quarter Ended 30 June 2022
July 28, 2022
View the PDF
Appendix 4C – Quarter Ended 31 March 2022
April 28, 2022
View the PDF
View the PDF
Appendix 4C – Quarter Ended 31 December 2021
January 31, 2022
View the PDF
View the PDF
Appendix 4C – Quarter Ended 30 September 2021
October 28, 2021
View the PDF
View the PDF
2021
Appendix 4C – Quarter Ended 30 June 2021
July 26, 2021
Appendix 4C – Quarter Ended 31 March 2021
April 27, 2021
Appendix 4C – Quarter Ended 31 December 2020
January 28, 2021
Appendix 4C – Quarter Ended 30 September 2020
October 27, 2020
View the PDF
View the PDF
2020
Appendix 4C – Quarter Ended June 2020
July 28, 2020
Appendix 4C – Quarter Ended March 2020
April 16, 2020
Appendix 4C – Quarter Ended 31 December 2019
January 22, 2020
View the PDF
View the PDF
Appendix 4C – Quarter Ended 30 September 2019
October 30, 2019
View the PDF
View the PDF
2019
Appendix 4C – Quarter Ended 30 June 2019
July 31, 2019
View the PDF
View the PDF
Appendix 4C – Quarter Ended 31 March 2019
30 April, 2019
View the PDF
View the PDF
Appendix 4C – Quarter Ended 31 December 2018
January 30, 2019
View the PDF
View the PDF
Appendix 4C – Quarter Ended 30 September 2018
October 16, 2018
View the PDF
View the PDF
2018
APPENDIX 4C – Quarter Ended 30 June 2018
July 23, 2018
View the PDF
View the PDF
APPENDIX 4C – Quarter Ended 31 March 2018
April 26, 2018
View the PDF
View the PDF
APPENDIX 4C – Quarter Ended 31 December 2017
January 30, 2018
View the PDF
View the PDF
APPENDIX 4C – Quarter Ended 30 September 2017
October 25, 2017
View the PDF
View the PDF
Glossary
| Acronym | Definition |
| 510(k) | Premarket Notification to the FDA, under Section 510(k) of the Food, Drug and Cosmetic Act, of intent to market a medical device in the USA |
| AGM | Annual General Meeting |
| ANZ | Australia and New Zealand |
| ARR | Annual Recurring Revenue |
| ASX | Australian Securities Exchange Limited |
| BAA | Business Associate Agreement |
| BCRL | Breast Cancer Related Lymphedema |
| EHR | Electronic Health Records |
| EMR | Electronic Medical Records |
| EPS | Earnings Per Share |
| FDA | Food and Drug Administration – USA |
| FY | Financial year (to 30 June) |
| Group | ImpediMed Limited and its wholly owned subsidiary companies |
| GST | Goods and Services Tax |
| HIP | Health Insurance Providers |
| HIPAA | Health Insurance Portability and Accountability Act |
| IDN | Integrated Delivery Network |
| IFRS | International Financial Reporting Standards |
| IP | Intellectual Property |
| ISO 13485 | Quality Management System for Medical Devices – Requirements for Regulatory Purposes |
| KMP | Key Management Personnel |
| L-Dex | Lymphedema Index Score |
| LE | Lymphedema |
| LTI | Long Term Incentive |
| MSA | Master Service Agreement |
| PHI | Protected Health Information |
| R&D | Research and Development |
| STI | Short Term Incentive |
| TCV | Total Contract Value |
| TGA | Therapeutic Goods Administration – Australia |
| UEL | Upper Extremity Lymphedema |